Differential expression of the RET gene in human acute myeloid leukemia

V. Gattei, M. Degan, D. Aldinucci, A. De Iuliis, F. Maria Rossi, F. Tassan Mazzocco, M. Rupolo, V. Zagonel, A. Pinto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing molecule of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors. We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1). To further verify the association between RET expression and the relative maturation stage of AML cells, we have performed a quantitative estimation of relative abundances of RET transcripts among various FAB subtypes of AMLs. By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quantitative RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amounts of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes. In addition, we provide evidence that the relative amounts of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes. These results indicate that RET expression in human AMLs is maturation-associated, probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.

Original languageEnglish
Pages (from-to)207-210
Number of pages4
JournalAnnals of Hematology
Volume77
Issue number5
DOIs
Publication statusPublished - Nov 1998

Fingerprint

Acute Myeloid Leukemia
Gene Expression
Developmental Genes
Phenotype
Granulocyte Precursor Cells
Acute Promyelocytic Leukemia
Proto-Oncogenes
Oncogene Proteins
Nerve Growth Factors
Receptor Protein-Tyrosine Kinases
Transforming Growth Factors
Myeloid Cells
Granulocytes
Leukemia
Polymerase Chain Reaction
Messenger RNA
Membranes
Genes

Keywords

  • Acute myeloid leukemia
  • RET
  • Tyrosine kinase

ASJC Scopus subject areas

  • Hematology

Cite this

Differential expression of the RET gene in human acute myeloid leukemia. / Gattei, V.; Degan, M.; Aldinucci, D.; De Iuliis, A.; Rossi, F. Maria; Tassan Mazzocco, F.; Rupolo, M.; Zagonel, V.; Pinto, A.

In: Annals of Hematology, Vol. 77, No. 5, 11.1998, p. 207-210.

Research output: Contribution to journalArticle

Gattei, V. ; Degan, M. ; Aldinucci, D. ; De Iuliis, A. ; Rossi, F. Maria ; Tassan Mazzocco, F. ; Rupolo, M. ; Zagonel, V. ; Pinto, A. / Differential expression of the RET gene in human acute myeloid leukemia. In: Annals of Hematology. 1998 ; Vol. 77, No. 5. pp. 207-210.
@article{1360b3dd09fd48c3acf8103db4bb3016,
title = "Differential expression of the RET gene in human acute myeloid leukemia",
abstract = "The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing molecule of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors. We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1). To further verify the association between RET expression and the relative maturation stage of AML cells, we have performed a quantitative estimation of relative abundances of RET transcripts among various FAB subtypes of AMLs. By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quantitative RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amounts of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes. In addition, we provide evidence that the relative amounts of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes. These results indicate that RET expression in human AMLs is maturation-associated, probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.",
keywords = "Acute myeloid leukemia, RET, Tyrosine kinase",
author = "V. Gattei and M. Degan and D. Aldinucci and {De Iuliis}, A. and Rossi, {F. Maria} and {Tassan Mazzocco}, F. and M. Rupolo and V. Zagonel and A. Pinto",
year = "1998",
month = "11",
doi = "10.1007/s002770050444",
language = "English",
volume = "77",
pages = "207--210",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Differential expression of the RET gene in human acute myeloid leukemia

AU - Gattei, V.

AU - Degan, M.

AU - Aldinucci, D.

AU - De Iuliis, A.

AU - Rossi, F. Maria

AU - Tassan Mazzocco, F.

AU - Rupolo, M.

AU - Zagonel, V.

AU - Pinto, A.

PY - 1998/11

Y1 - 1998/11

N2 - The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing molecule of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors. We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1). To further verify the association between RET expression and the relative maturation stage of AML cells, we have performed a quantitative estimation of relative abundances of RET transcripts among various FAB subtypes of AMLs. By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quantitative RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amounts of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes. In addition, we provide evidence that the relative amounts of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes. These results indicate that RET expression in human AMLs is maturation-associated, probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.

AB - The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing molecule of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors. We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1). To further verify the association between RET expression and the relative maturation stage of AML cells, we have performed a quantitative estimation of relative abundances of RET transcripts among various FAB subtypes of AMLs. By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quantitative RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amounts of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes. In addition, we provide evidence that the relative amounts of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes. These results indicate that RET expression in human AMLs is maturation-associated, probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.

KW - Acute myeloid leukemia

KW - RET

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=0031739635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031739635&partnerID=8YFLogxK

U2 - 10.1007/s002770050444

DO - 10.1007/s002770050444

M3 - Article

C2 - 9858145

AN - SCOPUS:0031739635

VL - 77

SP - 207

EP - 210

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -